{"text_format":"3","workbook":"xlsx","n_sheets":1,"sheets":["Sheet1"],"read":"whole","date_system":"1900"}

{"sheet":"Sheet1","index":0,"n_rows":11,"n_cols":13,"rows_kept":11,"merged":[[0,15,0,17],[10,11,16,11]]}
["Compound identifier","Trivial name",null,"ABS IC50 (nM)","ABS IC90 (nM)","ABS IC99 (nM)",null,"iGct IC50 (nM)","iGct IC90 (nM)","iGct IC99 (nM)",null,"Cav (nM)","Reference"]
[]
["MMV688533","MMV533",null,1.9,2.73,4.04,null,247.1,345,512,null,380,"Manuscript in preparation (MMV internal data)"]
["MMV674253","AZ412/MMV253",null,9,20.18,48.74,null,141.97,2325,4918,null,160,"BE Barber et al., Lancet Infect Dis 2022; 22: 879–90"]
["MMV643121","M5717 (DDD107498)",null,1,2,4.31,null,3.57,23.8,129,null,150,"JS McCarthy et al., Lancet Infect Dis 2021; 21: 1713–24"]
["MMV693183","MMV183",null,9.4,63.6,512.8,null,113,318.7,583.8,null,150]
["MMV390048","MMV048",null,24,51,116,null,171,1030,5000,null,140,"Sinxadi, Phumla, et al. \"Safety, tolerability, pharmacokinetics, and antimalarial activity of the novel Plasmodium phosphatidylinositol 4-kinase inhibitor MMV390048 in healthy volunteers.\" Antimicrobial agents and chemotherapy 64.4 (2020): 10-1128"]
["MMV390482","SJ733",null,30,66.7,159,null,102.7,547,3300,null,318," AH Gaur et al., Lancet Infect Dis 2020; 20: 964–75"]
["MMV018912","DSM265",null,4.3,5.99,8.6,null,5000,5000,5000,null,5800,"JS-McCarthy et al., Lancet Infect Dis 2017; 17: 626–35"]
[]
[{"$nulls":11},"Cav = Average human dose of exposure from clinical trials or volunteer infection studies"]